Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01631097 · ClinicalTrials.gov registry record · Phase 1
A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function
A Phase 1 study, sponsored by AVEO Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT01631097 is a Phase 1 study that has completed, run by AVEO Pharmaceuticals. The registered enrollment target is 44 participants.
The verdict
NCT01631097, a Phase 1 study, has completed, sponsored by AVEO Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This Phase 1, open-label, single dose study is designed to evaluate the pharmacokinetics, safety and tolerability of a single 1.5 mg tivozanib dose in subjects with varying degrees of hepatic impairment and normal hepatic function.
Interventions
- DRUG Tivozanib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01631097
The ClinicalTrials.gov registry entry for NCT01631097 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AVEO Pharmaceuticals, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tivozanib hydrochloride is the first listed.
NCT01631097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01631097 about?
NCT01631097 is a clinical study titled "A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function". This Phase 1, open-label, single dose study is designed to evaluate the pharmacokinetics, safety and tolerability of a single 1.5 mg tivozanib dose in subjects with varying degrees of hepatic impairment and normal hepatic function.
What is the current status of trial NCT01631097?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2012-05. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01631097?
The interventions under investigation include: Tivozanib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01631097?
This trial is sponsored by AVEO Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.